Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors Journal Article

Local Library Link: Find It @ Loyola

Authors: Kilianski, A; Baker, S. C.
Article Title: Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors
Abstract: To combat the public health threat from emerging coronaviruses (CoV), the development of antiviral therapies with either virus-specific or pan-coronaviral activities is necessary. An important step in antiviral drug development is the screening of potential inhibitors in cell-based systems. The recent emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) necessitates adapting methods that have been used to identify antivirals against severe acute respiratory syndrome coronavirus (SARS-CoV) and developing new approaches to more efficiently screen antiviral drugs. In this article we review cell-based assays using infectious virus (BSL-3) and surrogate assays (BSL-2) that can be implemented to accelerate antiviral development against MERS-CoV and future emergent coronaviruses. This paper forms part of a series of invited articles in Antiviral Research on "From SARS to MERS: 10years of research on highly pathogenic human coronaviruses."
Journal Title: Antiviral Research
Volume: 101
ISSN: 1872-9096; 0166-3542
Publisher: Elsevier Inc  
Journal Place: Netherlands
Date Published: 2014
Start Page: 105
End Page: 112
Language: eng
DOI/URL:

10.1016/j.antiviral.2013.11.004
Notes: LR: 20150114; CI: Copyright (c) 2013; GR: R01 AI085089/AI/NIAID NIH HHS/United States; GR: R01AI085089/AI/NIAID NIH HHS/United States; GR: T32 AI007508/AI/NIAID NIH HHS/United States; GR: T32 AI512795/AI/NIAID NIH HHS/United States; JID: 8109699; 0 (Antiviral Agents); NIHMS548240; OID: NLM: NIHMS548240; OID: NLM: PMC3931262; OTO: NOTNLM; 2013/10/04 [received]; 2013/10/31 [revised]; 2013/11/09 [accepted]; 2013/11/20 [aheadofprint]; ppublish